< GPCR News < GPCRs in Oncology and Immunology Lactate receptor GPR81 drives breast cancer growth and Here, we investigate the roles of GPR81 in three-dimensional (3D) and in vivo growth of breast cancer Methods: GPR81 was stably knocked down (KD) in MCF-7 human breast cancer cells which were subjected to Results: GPR81 was upregulated in multiple human cancer types and further upregulated by extracellular lactate and 3D growth in breast cancer spheroids.

Immunology Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer This abundance is exploited for cancer imaging, but there is interest in pharmacological inhibition of the NPYRs to interrogate their functional relevance in breast cancer. Therefore, these antagonists may aid in the development of novel cancer therapeutics and patient-based Tags Breast cancer , GPCR , Hypoxia , NPY , Neuropeptide .

Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer and is involved in several cancer phenotypes including tumor growth, survival, and metastasis. The roles of histamine and histamine receptor H1 (HRH1) in cancer pathogenesis remain controversial. Here, we show that HRH1 is widely expressed in various cancer cell lines and cancer tissues and that coexpression of CXCR4 and HRH1 is associated with poor prognosis in breast cancer.

in Oncology and Immunology Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer their respective di and mono-phosphate nucleoside forms, contributing significantly to immune biology, cancer

GPCRs in Oncology and Immunology Unveiling G-protein coupled receptors as potential targets for ovarian cancer analysis to in vitro validation Published date July 27, 2024 Abstract "Genetic heterogeneity in ovarian cancer To address the genetic heterogeneity of ovarian cancer, a future personalised approach could include the identification of unique GPCRs expressed in cancer biopsies, matched with personalised GPCR-targeted Subsequently, primary ovarian cancer cells derived from ascites and ovarian cancer cell lines were used

power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer highlights five GPCRs able to orchestrate tumor immunobiology at three main levels: tumor immunity, cancer Authors Donato Inverso, Carlotta Tacconi, Serena Ranucci, Marco De Giovanni Tags Angiogenesis , Cancer

and Immunology [1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer 7, 2023 Abstract "A3 adenosine receptor is an interesting target that showed controversial roles in cancer Compound 20 has been tested on both A3 adenosine receptor positive cancer cell lines (CHO-A3AR transfected , THP1 and HCCT26) and in A3 negative cancer cell lines, showing no effect on the latter and a proliferative Karl-Norbert Klotz , Sabrina Pacor , Stefano Moro , Giampiero Spalluto Tags A3 adenosine receptor , Cancer

< GPCR News < GPCRs in Oncology and Immunology Molecular characterization of breast cancer cell pools Abstract "Background: About one-third of patients with estrogen receptor alpha (ERα)-positive breast cancer PR is an important prognostic factor in breast cancer. New evidence has shown that progesterone (P4) has an anti-proliferative effect in ERα-positive breast cancer However, the role of PR in breast cancer is only poorly understood.

GPCRs in Oncology and Immunology Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer Increased VIPR2 mRNA expression and/or VIPR2 gene copy number has been documented in several cancers However, the pathophysiological role of increased VIPR2 in the proliferation of breast cancer cells remains In this study, we found that VIPR2 overexpression in MCF-7 and MDA-MB-231 cells, human breast cancer Increased VIPR2 also exacerbated intraperitoneal proliferation of breast cancer MDA-MB-231 cells in a

Patients' data on HCC were sourced from the Liver Hepatocellular Carcinoma-Japan (LIRI-JP) and The Cancer Sensitivity to immunotherapy and common antitumor drugs was predicted via the database Genomics of Drug Sensitivity in Cancer (GDSC). Patients in the high-risk group exhibited a worse prognosis but demonstrated a more favorable immunotherapy

Metallo-protease Peptidase M84 from Bacillusaltitudinis induces ROS-dependent apoptosis in ovarian cancer had no discernible impact on normal cell survival, but it specifically induced apoptosis in ovarian cancer PAR-1, a GPCR which is reported to be overexpressed in ovarian cancer cells, was identified as a target This evoked apoptotic death of the ovarian cancer cells through the intrinsic route. This established Peptidase M84 as a drug candidate for receptor mediated targeted-therapy of ovarian cancer

< GPCR News < GPCRs in Oncology and Immunology Prediction of survival and immunotherapy response by the Jia Feng , Feng Qin , Yanwen Yang , Chuanyuan Wei , Jianying Gu Tags G protein-coupled receptors , Immunotherapy , Melanoma , Multi-omics , Pan-cancer , Tumor microenvironment , scRNA-seq Source Contribute to the

< GPCR News < GPCRs in Oncology and Immunology Functional Assessment of Cancer-Linked Mutations in Sensitive Genetic variants in RGS proteins are associated with many diseases, including cancers, although the impact Intolerant and tolerant-control residues that overlap with pathogenic cancer mutations reported in the COSMIC cancer database were selected to define the functional phenotype. Identified intolerant residues with reported cancer-linked mutations RGS14-R173C/H and RGS4-K125Q/E126K

< GPCR News < GPCRs in Oncology and Immunology Colorectal cancer incidence trends in Golestan, Iran: the effects of factors including age, birth year (cohort) and diagnosis year (period) on colorectal cancer Methods: We obtained data on incidence cases of CRC from the Golestan Population-based Cancer Registry Weiderpass , Gholamreza Roshandel , Freddie Bray , Reza Malekzadeh Tags Age-Period-Cohort model , Colorectal Cancer

< GPCR News < GPCRs in Oncology and Immunology Esophageal and gastric cancer incidence trends in Golestan June 29, 2023 Abstract "Golestan province in the northeast of Iran is part of the Asian esophageal cancer belt and is known as a high-risk area for esophageal (EC) and gastric cancers (GC). on incident cases of EC and GC during 2004 to 2018 were obtained from the Golestan Population-based Cancer

< GPCR News < GPCRs in Oncology and Immunology GPR37 promotes colorectal cancer against ferroptosis by reprogramming lipid metabolism via p38-SCD1 axis Published date September 21, 2024 Abstract "Colorectal cancer Further tests showed that GPR37 protects cancer cells from ferroptosis by upregulating SCD1 expression

GPCRs in Oncology and Immunology Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling Published date June 21, 2024 Abstract "Colorectal cancer (CRC) remains a major global cause of cancer-related mortality, lacking effective biomarkers and therapeutic modulators play essential role within regulating downstream signaling of GPCR receptors, with function in cancers

receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis Published date June 18, 2024 Abstract " Background: Ovarian cancer (OV) is a common malignant Method: We downloaded data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases Li, Chunfang Ha Tags G protein-coupled receptor , Immune infiltration , Molecular marker , Ovarian cancer

< GPCR News < GPCRs in Oncology and Immunology NPFF stimulates human ovarian cancer cell invasion by Epithelial ovarian cancer (EOC) is a leading cause of death among gynecological malignancies. Fang , Peter C K Leung , Jung-Chien Cheng Tags Invasion , MMP-9 , NPFFR2 , Neuropeptide FF , Ovarian cancer

and Immunology Systems Pharmacodynamic Model of Combination Gemcitabine and Trabectedin in Pancreatic Cancer prior study, we reported the synergistic cytotoxic effects of gemcitabine and trabectedin on pancreatic cancer analysis was performed, and a system pharmacodynamics model (SPD) was developed to capture pancreatic cancer Straubinger , William J Jusko Tags Systems Pharmacodynamic , drug combination , gemcitabine , pancreatic cancer

Oncology and Immunology Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer adenocarcinoma (PDAC) remains an aggressive disease that is expected to become the second cause of cancer siRNA-mediated knockdown of YES1, and transfection of epitogue-tagged YAP mutants in PANC-1 and Mia PaCa-2 cancer

protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer Published date September 21, 2023 Abstract "Objectives: Lung cancer is a major public health concern and represents the most common cause of cancer-related death worldwide. protein-coupled receptor 37 (GPR37) exhibits unknown functions in tumors, particularly in non-small-cell lung cancer

guanylate kinase (MAGUK) scaffold protein, and protein kinase A anchoring protein (AKAP) 5 in MCF7 breast cancer β1-adrenergic receptor (β1AR) are G protein-coupled receptors (GPCR) that are implicated in breast cancer MCF7 breast cancer cells express GPR30, β1AR, MAGUKs, and AKAP5 in the plasma membrane, and co-immunoprecipitation Stephen Serafin , Tobias Schmidt , Björn Olde , Kathleen M Caron , L M Fredrik Leeb-Lundberg Tags Breast cancer

coupled receptors (GPCRs) in breast cancer, and his interest in pancreatic cancer. as a potential drug target due to its high expression in triple negative breast cancer. Mike then transitioned to pancreatic cancer, questioning why genes are dysregulated in cancer, which led him to explore different aspects of gene regulation and its relation to cancer progression. fibroblasts and is crucial for their function, leading to complications in cancer patients.

GPCRs in Oncology and Immunology Gi/o GPCRs drive the formation of actin-rich tunneling nanotubes in cancer Using a model of human adrenocortical cancer cells, here we established that activation of the GPCR OXER1

GPCR News < GPCRs in Oncology and Immunology A2aR on lung adenocarcinoma cells: A novel target for cancer

A large component of his work is centered around dysregulated signaling in cancer and the development of novel mechanism-based cancer therapies. Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications More J Silvio Gutkind on LinkedIn Gutkind Lab on Twitter UCSD Moores Cancer Center Dr.

Oncology and Immunology Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer